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There is an increased incidence of heart disease in patients
with chronic nephrotic syndrome (NS), which may be
attributable to the malnutrition and activated inflammatory
state accompanying the sustained proteinuria. In this study,
we evaluated renal function, cardiac morphometry,
contractile function, and myocardial gene expression in the
established puromycin aminonucleoside nephrosis rat model
of NS. Two weeks after aminonucleoside injection, there was
massive proteinuria, decreased creatinine clearance, and a
negative sodium balance. Skeletal and cardiac muscle
atrophy was present and was accompanied by impaired left
ventricular (LV) hemodynamic function along with decreased
contractile properties of isolated LV muscle strips. The
expression of selected cytokines and proteins involved in
calcium handling in myocardial tissue was evaluated by real
time polymerase chain reaction. This revealed that the
expression of interleukin-1b, tumor necrosis factor-a, and
phospholamban were elevated, whereas that of cardiac
sarco(endo)plasmic reticulum calcium pump protein was
decreased. We suggest that protein wasting and systemic
inflammatory activation during NS contribute to cardiac
remodeling and dysfunction.
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In the nephrotic syndrome (NS), massive proteinuria is
accompanied by hypoproteinemia, protein wasting, and lean
body mass reduction.1–3 Anorexia and impaired intestinal
absorption from the edematous gut are also contributory,
inducing malnutrition.4,5 Inflammatory activation, which
frequently follows malnutrition, has been consistently
reported in the NS. Plasma and urinary levels of tumor
necrosis factor-a (TNF-a) are elevated in patients with NS6,7
as well as the glomerular expression of TNF-a and
interleukin-1b (IL-1b) in experimental models of NS.8 In
addition, treatment with TNF-a blocking agents ameliorates
NS in both animal models and patients with corticosteroid-
resistant NS.9,10
Proinflammatory cytokines, such as TNF-a, are major
determinants of cachexia in several chronic diseases.11,12
Circulating levels of TNF-a are elevated not only in the NS
but also in patients with heart failure.13,14 In the heart, TNF-
a has a negative inotropic effect on cardiomyocytes15,16 and
its local overexpression in transgenic mice leads to progres-
sive dilatation and failure.17,18 Nevertheless, the increased
incidence of heart disease in patients with chronic NS has
been mainly attributed to coronary disease induced by
dyslipidemia and hypercoagulability.19,20 Recent evidences do
not entirely support, however, this view. Serum lipids and
lipoproteins are not significant predictors of endothelial
dysfunction in patients with NS21 and high cardiovascular
mortality associated with proteinuria is not explained by the
presence of classic cardiovascular risk factors such as
hypertension or smoking.19 In addition, a high incidence of
unexplained cardiac disease has also been reported in
children with focal segmental glomerulosclerosis.22
This study was undertaken in order to clarify the impact
of protein wasting and inflammatory activation that
accompany the NS on cardiac remodeling and myocardial
function. Namely, we evaluated cardiac hemodynamics,
contractile function of multicellular myocardial preparations,
morphometric parameters, and myocardial gene expression
of cytokines, growth factors, type B natriuretic peptide
(BNP), myosin heavy-chain (MHC) isoforms, and calcium-
handling genes in the well-established model of puromycin
aminonucleoside (PAN)-induced NS.
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RESULTS
Renal function, sodium balance, and sympathetic activity
PAN injection induced creatinine clearance reduction and
massive proteinuria, present both 7 and 14 days after
injection, whereas the disturbance of sodium handling was
biphasic. On day 7, PAN-treated rats presented decreased
fractional excretion of sodium (FENaþ ), positive sodium
balance, and marked ascites, whereas on day 14 FENaþ was
increased, sodium balance was negative, and there was a
reduction in ascites volume. Urinary noradrenaline was
increased during the first 3 days after PAN injection and was
decreased on days 7–9 after PAN injection (Table 1 and
Figure 1).
Cardiac and skeletal muscle atrophy
On day 14, PAN-treated rats presented gastrocnemius and
cardiac atrophy, with decreased organ weight to tibial length
ratios and lower protein concentration to DNA concentration
ratios. Gastrocnemius muscle atrophy was accompanied by
decreased DNA content and cell size. Differently, cardiac
atrophy was associated with increased cell size, but with no
changes in DNA content. No significant fibrosis was detected
in the myocardium of PAN-treated rats (Tables 1 and 2 and
Figure 2).
Non-invasive blood pressure and cardiac hemodynamics
Non-invasive blood pressure recordings did not differ
between the studied groups at both days 7 and 14. Heart
rate was also similar between Control and PAN-treated rats
14 days after injection (41479 and 389726, respectively;
beats/min) (Table 1).
PAN-treated rats presented basal hemodynamic recordings
similar to Control rats and showed disturbed left ventricular
(LV) systolic and diastolic function indexes only in isovolu-
metric (ISO) test heartbeats. Elevations of end-diastolic
pressure (EDP) after an ISO cycle revealing diastolic
intolerance to afterload (DIA) were already present 7 days
after PAN injection, but most hemodynamic changes were
apparent only 14 days after injection, with lower maximum
pressure (Pmax), peak rate of pressure rise (dP/dtmax), and
absolute peak rate of pressure fall (dP/dtmin), and higher time
constant t, in ISO beats. Of note, hemodynamic disturbances
were observed in the absence of significant differences in
basal EDP and Pmax (Table 3).
Contractile function of myocardial multicellular preparations
The contractile function of muscle strips from the LV
myocardium was impaired 14 days after PAN injection. In
fact, there was a significant reduction of both contractility
and relaxation indexes, as evidenced by lower basal active
tension (AT), peak isotonic shortening and maximum
velocity of shortening (dL/dtmax), and lower absolute
maximum velocity of lengthening (dL/dtmin), respectively.
Trends toward decreased maximum velocity of tension rise
(dT/dtmax) (P¼ 0.17) and absolute maximum velocity of
tension fall (dT/dtmin) (P¼ 0.06) were also observed
(Table 4).
The changes in AT in response to increasing stimulation
frequencies were also distinct between Control and PAN-
treated groups. The force–frequency relationship (FFR) was
positive in the LV myocardium of Control rats, whereas in
PAN group developed AT did not vary significantly with
increasing stimulation frequencies (Figure 3).
Myocardial gene expression
LV gene expression of BNP, MHC, calcium-handling genes,
and cytokines was altered after PAN injection, whereas no
differences were observed for pre-pro-endothelin 1 and
insulin-like growth factor 1 (IGF-1). BNP mRNA levels were
Table 1 | Body weight, sodium balance, edema, renal function, and blood pressure in PAN nephrosis, 7 and 14 days after
injection
7 days 14 days
Control PAN Control PAN
Body weight, g 22175 24874* 24172 23475
Na+ balance, mmol/24 h 0.0370.07 0.9070.07* 0.1870.13 0.6170.38*
FENa+, % 0.1470.01 0.0470.01* 0.1770.03 0.5370.14*
Ascites, g 0.770.1 14.571.1* 0.670.1 1.370.3*
Creatinine clearance, ml/min 5.6571.38 2.2470.81* 4.5171.08 2.2470.32*
Urinary proteins, mg/24 h/mg creatinine 3.470.3 37.871.8* 3.870.7 51.079.0*
Systolic BP, mm Hg 15578 14776 13874 15077
Diastolic BP, mm Hg 10679 8678 8673 8677
BP, blood pressure; FE Na+, fractional excretion of sodium; PAN, puromycin aminonucleoside.
Values are mean7s.e. of six experiments per group.
*Po0.05 vs Control rats.
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Figure 1 | Urinary excretion of sodium and urinary levels of
noradrenaline in PAN and Control rats throughout the study.
*Po0.05 vs Control rats.
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Table 2 | Characterization of cardiac (LV) and skeletal muscle atrophy in PAN nephrosis, 7 and 14 days after injection
7 days 14 days
Control PAN Control PAN
Heart weight, mg 811.4723.9 770.7721.6 828.0723.9 661.7728.7*
Heart weight/tibial length, mg/mm 239.4710.2 236.6715.5 244.6710.2 203.377.5*
LV weight/tibial length, mg/mm 169.476.5 166.9711.5 174.276.6 144.475.6*
LV-Cprotein/LV-CDNA 96.073.7 96.673.5 96.273.0 69.874.4*
LV protein content, mg 20.870.9 21.871.1 21.570.9 14.970.8*
LV DNA content, mg 0.2270.01 0.2370.01 0.2270.01 0.2270.01
Gast weight/tibial length, mg/mm 40875 374726 458711 206752*
Gast-Cprotein/Gast-CDNA 229.2720.0 224.3716.7 226.9720.1 161.1719.8*
Gast protein content, mg 50.771.6 43.972.7 52.971.9 26.971.1*
Gast DNA content, mg 0.2270.02 0.2070.01 0.2370.02 0.1970.01*
C, concentration; Gast, gastrocnemius muscle; LV, left ventricle; PAN, puromycin aminonucleoside.
Values are mean7s.e. of six experiments per group.
*Po0.05 vs Control rats.
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Figure 2 | Histology of the left ventricle (LV) and gastrocnemius muscle in PAN nephrosis, 14 days after injection. Cell transversal
diameter of (a) cardiac (original magnification  400 amplification, left ventricle) and (b) gastrocnemius muscle (original magnification
 200 amplification) cells, with respectively representative photographs. *Po0.05 vs control rats.
Table 3 | LV hemodynamics in PAN nephrosis, 7 and 14 days after injection
Basal ISO
Control PAN Control PAN
7 days after injection
EDP, mm Hg 1.670.8 3.170.1 2.670.3 3.670.4
Pmax, mm Hg 102.179.6 101.0710.9 190.2722.4
w 194.8719.5w
dP/dtmax, mm Hg/s 45937856 51897627 58037772 63687558
dP/dtmin, mm Hg/s 29077591 29217462 42857650w 41917344w
Time constant t, ms 23.372.8 22.270.6 21.272.5 20.771.7
DIA, mm Hg — — 0.270.1 1.770.6*
14 days after injection
EDP, mm Hg 2.170.4 3.370.6 2.770.3 4.070.7
Pmax, mm Hg 101.979.1 84.177.1 205.275.5
w 164.8714.2*w
dP/dtmax, mm Hg/s 47257437 34117501 57847533 40127398*
dP/dtmin, mm Hg/s 28537475 22847216 42707355w 27177404*
Time constant t, ms 22.671.9 23.171.2 20.471.2 33.773.2*w
DIA, mm Hg — — 0.270.2 1.970.4*
DIA, diastolic intolerance to afterload; dP/dtmax and dP/dtmin, peak rates of pressure rise and fall, respectively; EDP, end-diastolic pressure; ISO, isovolumetric test heartbeat;
LV, left ventricle; PAN, puromycin aminonucleoside; Pmax, maximum pressure.
Values are mean7s.e. of six experiments per group.
*Po0.05 vs Control rats; wPo0.05 vs basal heartbeat.
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selectively elevated on day 7 in PAN-treated rats. MHC-a
expression was also altered only on day 7, with decreased
mRNA levels. Regarding calcium-handling genes, we detected
sarcoplasmic reticulum calcium ATPase isoform 2a (SER-
CA2a) downregulation and phospholamban (PLB) upregula-
tion 7 and 14 days after injection, whereas no significant
differences were observed for Naþ /Ca2þ exchanger. Cyto-
kine gene expression was also altered in PAN-treated rats:
mRNA levels of TNF-a and IL-1b were upregulated, whereas
no significant differences were observed for IL-6 and IL-1a
(Figure 4).
Myocardial protein expression
Decreased myocardial LV SERCA2a protein levels were
detected in PAN group, 14 days after injection, with no
significant differences in PLB expression between Control
and PAN groups. This resulted in a reduction of SERCA2a to
PLB ratio in the PAN group (Figure 5).
DISCUSSION
PAN injection resulted in severe proteinuria and impaired
creatinine clearance. As previously reported by others,23 we
found that the time course of variations of sodium retention
and ascites accumulation in PAN nephrosis was divided into
two phases. The first phase, from days 2 to 8, was marked by
the decrease of sodium excretion accompanied with positive
sodium balance and ascites accumulation. The second phase,
from days 10 to 14, was marked by almost complete recovery
of ascites, despite persistent high proteinuria. During this
phase, urinary sodium excretion increased progressively
toward higher than control levels from days 12 to 14, so
that sodium balance was negative during this period. Most of
the available evidence implicates a primary renal sodium
handling abnormality in this edema formation condition.24
In order to clarify the mechanisms underlying sodium
balance regulation in PAN nephrosis, we studied sympathetic
activity during the time span of the study. Interestingly,
noradrenaline was reduced in 24 h urine during the second
week after PAN injection, indicating that decreased sympa-
thetic activity could contribute to negative sodium balance
and increased FENaþ from days 10 to 14.
Skeletal muscle atrophy, reduced gastrocnemius protein
concentration to DNA concentration ratio, and reduced
gastrocnemius cell size were observed in PAN-treated group
on day 14. These findings agree well with previous
observations in the passive Heymann nephritis model of
NS, providing evidence for impaired muscle protein synth-
esis.3 In our study, cardiac atrophy paralleled skeletal muscle
atrophy in PAN-treated rats. This was not accompanied by
LV decreased DNA content indicating that, LV cell death may
not be present. Interestingly, the MHC-a gene, that codes a
key component of the contractile apparatus and one of the
most abundant proteins of cardiomyocytes, was down-
regulated on day 7 in PAN-injected rats, preceding cardiac
atrophy. Although, to our knowledge, cardiac atrophy was
never described in PAN nephrosis, van der Vijgh et al.25 have
previously shown morphometrically measurable cardiac
abnormalities in PAN nephrosis 14 days after injection,
namely an increase of the nuclear and reticulin indexes.
Unloading is not a plausible explanation for cardiac atrophy,
given the absence of significant differences in EDP between
Control and PAN-injected rats. However, it should be noted
that we did not assess LV volume and therefore could not
rigorously assess LV preload. Although systolic and diastolic
LV function was not significantly altered, impaired functional
reserve was uncovered by hemodynamic stress with ISO
beats. In fact, acute afterload elevations generating ISO cycles
yielded lower dP/dtmax and Pmax, decreased relaxation rate
and increased diastolic intolerance to afterload in PAN-
treated rats on day 14. The only hemodynamic disturbance
present on day 7 was the elevation of diastolic intolerance to
afterload after an ISO cycle, denoting diastolic intolerance to
Table 4 | Contractile parameters of myocardial (LV)
multicellular muscle preparations in PAN nephrosis, at basal
stimulation frequency (0.5 Hz), 14 days after injection
Control PAN
AT, mN/mm2 0.8070.30 0.2270.08*
dT/dtmax, mN/mm
2/s 11.275.0 4.071.7
dT/dtmin, mN/mm
2/s 14.175.3 4.171.7
tHR, ms 116.979.4 117.471.0
PS, %Lmax 5.0071.65 0.5170.23*
dL/dtmax, Lmax/s 1.0770.35 0.1170.05*
dL/dtmin, Lmax/s 1.0270.36 0.0770.03*
tdL/dtmin, ms 114.0710.5 119.274.6
AT, active tension; dL/dtmax and dL/dtmin, maximum velocity of shortening and
lengthening, respectively; dT/dtmax, and dT/dtmin, maximum velocity of tension rise
and decline, respectively; Lmax, maximum length; PS, peak isotonic shortening;
tdL/dtmin, time to dL/dtmin; tHR, time to half relaxation.
Values are mean7s.e. of six experiments per group.
*Po0.05 vs Control rats.
0.0 0.5 1.0 1.5 2.0 2.5 3.0
-40
-30
-20
-10
0
10
20
30
40
50
60
70
80
90
‡ControlPAN
‡
*
†
*
Frequency 
(Hz)
∆ 
Ac
tiv
e
 te
ns
io
n
(%
)
Figure 3 | FFRs obtained in multicellular muscle preparations
from the LV myocardium in PAN nephrosis, 14 days after
injection. Results are presented as percent variation from baseline
AT at 0.5 Hz. wPo0.05 for interaction with two-way repeated
measures analysis of variance; *Po0.05 vs Control rats at an
equivalent frequency of stimulation; zPo0.05 vs 1 Hz, as evaluated
with the Student–Newman–Keuls method for multiple group
comparisons.
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acute afterload. We have previously proposed that this
response to acute afterload elevations can be a precocious
sign of dysfunction, preceding overt heart failure.26
To evaluate the intrinsic myocardial contractile function of
PAN-treated rats, we used isolated multicellular preparations.
Contractility, relaxation and FFRs were disturbed in the
muscle strips of PAN-treated rats on day 14. Indeed, the
positive FFR is an important intrinsic regulatory mechanism
of cardiac contractility.27 When it disappears or is inverted
and becomes negative a central role is attributed to changes
in calcium kinetic regulatory proteins such as SERCA2a.27
Interestingly, we observed reduced levels of both SERCA2a
mRNA and protein. Other authors have shown contractile
function to be preserved on isolated papillary muscle
experiments despite atrophic remodeling, 14 days after
heterotopic heart transplantation.28 These results suggest
that mechanisms other than cardiac atrophy may contribute
to myocardial dysfunction in PAN nephrosis.
In order to clarify the molecular mechanisms underlying
cardiac remodeling, we evaluated both cardiac histology and
myocardial gene expression. Regarding myocardial histology,
we found increased cardiomyocyte diameter in the absence of
significant fibrosis. This probably indicates enhanced cardi-
omyocyte edema, which could account for myocardial
dysfunction. In fact, cardiac edema has been shown to
increase myocardial stiffness and induce contractile dysfunc-
tion.29 This has been attributed to increased myocardial
expression of aquaporins.29 Sympathetic activity is altered in
PAN rats throughout the experiment, although the urinary
levels of noradrenaline were similar between PAN and control
rats on day 14. We cannot exclude that these changes in
sympathetic activity may have influenced heart function
throughout the study. Additionally, proinflammatory cyto-
kines, TNF-a and IL-1b, were upregulated in the LV
myocardium of PAN-treated rats. These results mimic the
pattern of cytokine activation in the glomeruli of rats injected
with PAN,8 and might partly be explained taking in account
that increased circulating levels of TNF-a were reported in
the NS6,7 and that TNF-a induces its own expression even in
remote organs.30 Local production of proinflammatory
cytokines such as TNF-a in the heart is potentially relevant
given its well-known effects in cardiac remodeling and
contractile dysfunction.13–16 Moreover, TNF-a is a major
determinant of cachexia in several chronic diseases.11,12
Disturbed cardiomyocyte calcium kinetics have also been
implicated in the origin of myocardial dysfunction during
heart failure progression.26 In our study, cardiac atrophy was
accompanied by decreased gene and protein expression of
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SERCA2a, the main protein involved in calcium reuptake to
the sarcoplasmic reticulum in the cardiomyocytes, and by
increased mRNA levels and identical protein levels of its
main inhibitor, PLB. The SERCA2a protein to PLB protein
ratio was decreased. These results suggest that disturbed
cardiomyocyte calcium kinetics could underlie myocardial
dysfunction.
Although we did not evaluate the circulating levels of
growth hormone and IGF-1, the absence of changes in LV
IGF-1 mRNA levels in PAN-treated rats suggests that this
pleitropic growth factor is not involved in cardiac remodel-
ing. Nevertheless, we cannot exclude a systemic disturbance
of the growth hormone/IGF-1 axis, as increased renal
excretion and reduced circulating levels of IGF-1 and IGF-
binding proteins have been reported in the NS.31,32 This
disturbance might contribute to growth and development
retardation described both in experimental models and in
children with poorly controlled NS.5,33 We did not observe
growth retardation, as estimated by tibial length, in PAN-
treated rats. Still, the short time span of our study and the
restriction of food ingestion in the Control group can explain
this result. Given that anorexia contributes to the malnutri-
tion observed in the NS, the control of food intake might
have been particularly relevant.34
Elevated circulating levels of natriuretic peptides have
been consistently observed in the NS.35,36 Although the exact
mechanisms underlying the activation of this natriuretic
system are still unclear, myocardial stretch is unquestionably
one of the main triggers for natriuretic peptide synthesis and
release, both in vitro and in vivo.37,38 In our study, we
observed myocardial BNP overexpression in the initial phase
of positive sodium balance and maximal edema (day 7).
However, no significant changes in EDP or in blood pressure
were present, suggesting absence of cardiac volume overload.
These results support the observation that sodium retention,
interstitial volume expansion, and edema formation are not
uniformly accompanied by plasma volume expansion,39 and
suggest that factors other than myocardial stretch may
stimulate natriuretic peptide system activation in the NS.
In agreement with this latter view, proinflammatory
cytokines, such as TNF-a and IL-1b, that have been shown
to selectively upregulate BNP at the transcriptional and
translational levels in cardiomyocytes,40,41 were locally over-
expressed in the heart of PAN-treated rats. Moreover, sodium
renal loss and possible reduction of extracellular volume may
explain why EDP was not elevated in the intact heart of PAN-
injected rats at day 14 despite diastolic dysfunction, and may
explain why myocardial BNP levels were upregulated at day 7,
but not at day 14 after PAN injection.
Finally, the possibility that cardiac remodeling and
contractile dysfunction could have resulted from direct
cardiac effects of PAN must be addressed. PAN nephrosis is
a commonly used and well-established experimental model
of NS. Chemically, PAN is a nucleoside-like fragment
structurally analogous to adenosine derived from puromycin
by hydrolytic cleavage.42 Although it shares some of the
biological properties of puromycin, PAN is not a specific
inhibitor of protein biosynthesis.43–46 In fact, PAN does not
inhibit de novo protein synthesis in either primary rat
hepatocyte cultures47 or rat thymocytes undergoing apopto-
sis.48 Moreover, atrophy was not reported uniformly among
organs in PAN nephrosis. Indeed, increased liver weight and
hepatocyte protein synthesis have been demonstrated in this
experimental model.49 Furthermore, approximately 80% of
PAN is excreted in the urine and feces within 24 h of
administration in the rat, although most of the functional
and structural changes were observed 14 days after
injection.50
In conclusion, our results show that the proinflammatory
state induced by PAN nephrosis involves the heart and is
accompanied by cardiac remodeling and dysfunction. This
might constitute a new mechanism underlying cardiac
changes and cardiovascular risk in patients with NS.
MATERIALS AND METHODS
Animal experiments were performed according to the Portuguese
law on animal welfare and conform to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals (NIH
Pub. no. 85-23, Revised 1996). Normotensive male Sprague–Dawley
rats (n¼ 36; Harlan, Interfauna Ibe`rica, Barcelona, Spain), with a
body weight of 200–220 g, were enrolled after a 7-day period of
stabilization and adaptation to blood pressure measurements. The
animals were kept under controlled environmental conditions
(12:12 h light/dark cycle and 22721C room temperature).
Experimental model
The animals (n¼ 6 in each group) were studied 7 and 14 days after a
single intraperitoneal injection of 150 mg/kg of PAN (Sigma-
Aldrich, St Louis, MO, USA) or the same volume of vehicle (NaCl
0.9%). PAN-treated rats were fed ad libitum throughout the study
with ordinary rat chow (0.19% sodium; Panlab, Barcelona, Spain).
In order to control anorexia and sodium intake, the daily intake of
rat chow in the Control group was limited to the intake of PAN
group. Blood pressure and heart rate were measured using a
photoelectric tail-cuff pulse detector (LE 5000, Letica, Barcelona,
Spain) in conscious restrained animals. The animals were then
placed in metabolic cages (Techniplast, Buguggiate, Italy) for 24 h
urine collection. Finally, under anesthesia with sodium pentobarbi-
tal (50 mg/kg, intraperitoneal) LV hemodynamic parameters were
assessed, blood was collected from the heart, morphometric
measurements were performed, and LV samples were collected for
molecular analysis. In an additional group of animals, the
mechanical function of myocardial multicellular preparations was
studied 14 days after injection of PAN (n¼ 6) or vehicle (n¼ 6).
Serum and urine biochemistry and edema formation
Quantification of sodium, creatinine, and total proteins was
performed using Cobas Mira Plus analyzer (Horiba, ABX Diag-
nostics, Montpelier, France). Creatinine clearance, FENaþ , and
sodium balance were determined. Ascites volume was measured
moistening and weighing an absorbent paper. Quantification of
noradrenaline in urine was performed by high-performance liquid
chromatography with electrochemical detection, as described
previously.51 In our laboratory, the lower limit of detection of
noradrenaline ranged from 350 to 1000 fmol.
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Morphometric analysis
The LV was weighted after dissecting the right ventricular free wall.
Gastrocnemius muscle weight and tibial length were also measured.
Histology
Gastrocnemius and cardiac muscle sections (Microm STS HM340E,
Walldorf, Germany), 4 mm thick, of paraffin-embedded formalin-
fixed specimens were deparaffinized in xylene and rehydrated
through graded ethanol. The sections were then stained with
hematoxylin and eosin (Microm), and the smallest cardiomyocyte
and gastrocnemius muscle cell transversal diameters were measured
(Leica Application Suite Software, Leica Microsystems, Wetzlar,
Germany). Collagen detection with Masson’s trichrome staining
(Bio-Optica, Milan, Italy) was performed to evaluate interstitial
myocardial fibrosis.
Quantification of total protein and DNA concentration
Right gastrocnemius and LV samples were weighed (B12 mg),
pulverized, and their protein and DNA concentration were
determined. Protein quantification was performed after sample
homogenization in a 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (50 mM) buffer (150 KCl, 1.0 benzamidine, 0.1 EGTA, 1.0
PMSF, 1.0 DTT, and 0.1 CLAP; in mM), according to the Bradford
method (Bio-Rad, Hercules, CA, USA) using bovine serum albumin
as standard. Total DNA quantification was performed after sample
homogenization and genomic DNA extraction (Bio-Rad) through
ultraviolet spectrophotometry (Eppendorf, Hamburg, Germany).
The DNA content was used as a surrogate of muscle cell number,52
whereas the protein concentration to DNA concentration ratio was
used as an index of cell size.53
Immunoblotting
LV free wall sample lysates were boiled in sample buffer (Bio-Rad) at
951C for 5 min. Samples containing 40 mg of cell protein were
separated by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis with 12% polyacrylamide gel and then electroblotted onto
nitrocellulose membranes (Bio-Rad). Blots were blocked 1 h with
2% non-fat dry milk in Tris-buffered saline (50 mM Tris-HCl,
150 mM NaCl, pH 7,4) at room temperature with constant shaking.
Blots were then incubated with anti-SERCA2a polyclonal antibody
(1:200; Affinity Bioreagents, Golden, CO, USA) anti-PLB (1:2000,
Cyclacel, Dundee, UK), and anti-glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) (1:2000; Abcam, Cambridge, UK) in 2% non-
fat dry milk in Tris-buffered saline-T overnight at 41C. The
immunoblots were subsequently washed and incubated with
fluorescently labeled goat anti-mouse secondary antibody (1:5000;
AlexaFluor 680, Molecular Probes, Prat de Llobregat, Barcelona,
Spain) or the fluorescently labeled goat anti-rabbit (1:10 000;
IRDyeTM 800, Rockland, PA, USA) for 60 min at room temperature
and protected from light. The membrane was washed and imaged by
scanning at both 800 and 700 nm, with an Odyssey Infrared Imaging
System (LI-COR Biosciences, Lincoln, NE, USA).
Relative quantification of mRNA
Transmural LV free wall samples were collected, immersed in
RNAlater (Qiagen, Hilden, Germany), and frozen (801C). Total
mRNA was extracted through the guanidium thiocyanate selective
silica-gel membrane-binding method (Qiagen), according to the
manufacturer’s instructions. Concentration and purity were assayed
by spectrophotometry (Eppendorf). Two-step real-time reverse
transcription-polymerase chain reaction (PCR) was used to perform
relative quantification of mRNA. For each studied mRNA molecule,
standard curves were generated from the correlation between the
amount of starting total mRNA and PCR threshold cycle (second
derivative maximum method) of graded dilutions from a randomly
selected tissue sample (r40.97). For relative quantification of
specific mRNA levels, 50 ng of total mRNA from each sample
underwent two-step real-time reverse transcription-PCR. A melt
curve analysis of each real-time PCR and 2% agarose gels (0.5 mg/ml
ethidium bromide) was performed to exclude primer-dimer
formation and assess the purity of the amplification product.
GAPDH mRNA levels were similar in all experimental groups,
which enabled the use of this gene as internal control. Results of
mRNA quantification are expressed in an arbitrary unit (AU) set as
the average value of the Control group (Control¼ 1 AU), after
normalization for GAPDH. Reverse transcription (20 ml; 10 min at
221C, 50 min at 501C, and 10 min at 951C) was performed in a
standard thermocycler (Whatman Biometra, Goettingen, Germany):
40 U/reaction of reverse transcriptase (Invitrogen, Prat de Llobregat,
Barcelona, Spain), 20 U/reaction of RNase inhibitor (Promega, WI,
USA), 30 ng/ml random primers (Invitrogen), 0.5 mM nucleotide
mix (MBI Fermentas, Corston Bath, UK), 1.9 mM MgCl2, and 10 mM
DTT. Ten percent of the cDNA yield was used as a template for real-
time PCR (LightCycler, Roche, Indianapolis, IN, USA) using SYBR
green (Qiagen), according to the manufacturer’s instructions.
Specific PCR primer pairs for the studied genes were as follows:
GAPDH – forward (fw) 50-TGG CCT TCC GTG TTC CTA CCC-30
and reverse (rev) 50-CCG CCT GCT TCA CCA CCT TCT-30; IGF-1
–fw 50-CAG ACG GGC ATT GTG GAT-30 and rev 50-AGT CTT GGG
CAT GTC AGT GTG-30; pre-pro-endothelin 1 – fw 50-CCA TGC
AGA AAG GCG TAA AAG-30 and rev 50-CGG GGC TCT GTA GTC
AAT GTG-30; IL-1a – fw 50-GAG AGC CGG GTG GTG GTG TC-30
and rev 50-TCT GGG TTG GAT GGT CTC TTC TAA-30; IL-1b – fw
50-ATG GCA ACT GTC CCT GAA CTC-30 and rev 50-AAT CCT
TAA TCT TTT GGG GTC TG-30; IL-6 – fw 50-CCG TTT CTA CCT
GGA GTT TG –30 and rev 50-GAA GTT GGG GTA GGA AGG AC-30;
TNF-a – fw 50-GGG GGC CTC CAG AAC TCC A-30 and rev 50-TGG
GCT ACG GGC TTG TCA-30; MHC-a – fw 50-CGA AGC GTG TCA
TCC AGT-30 and rev 50-CTC CAG AGC AGG GTT AGC-30; MHC-b
– fw 50-TGC TGA CAG ATC GGG AGA ACC-30 and rev 50-TGG
CAG CAA TAA CAG CAA AAT-30; SERCA2a –fw 50-CGA GTT GAA
CCT TCC CAC AA-30 and rev 50-GGA GGA GAT GAG GTA GCG
GAT GGA-30; Naþ /Ca2þ exchanger – fw 50-CTG GAG CGC GAG
GAA ATG TTA-30 and rev 50-GAC GGG GTT CTC CAA TCT
CAA-30; PLB – fw 50-GGC ATC ATG GAA AAA GTC CA-30 and rev
50-GGT GGA GGG CCA GGT TGT AA-30; BNP – fw 50-GGA CCA
AGG CCC TAC AAA AGA-30 and rev 50-CAG AGC TGG GGA AAG
AAG AG-30.
Hemodynamic studies
Animals were placed on a heated plate (body temperature 36–381C)
and the trachea was cannulated (Abocaths 16G) for mechanical
ventilation (60 c.p.m.; tidal volume of 1ml /100g; Harvard Small
Animal Ventilator, Model 683) with oxygen-enriched air. Respira-
tory rate and tidal volume were adjusted to keep arterial blood gases
and pH within physiological limits. The heart was then exposed
through a median sternotomy and the pericardium widely opened.
The ascending aorta was carefully dissected to allow its occlusion
during the experimental protocol. LV pressures were measured with
a 2-Fr high-fidelity micromanometer (SPR-324, Millar Instruments,
Houston, TX, USA), inserted through the apex. After complete
instrumentation, the animal preparation was allowed to stabilize for
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15 min. Afterload elevations were performed by abrupt occlusion of
the ascending aorta during diastole. The first heartbeat following
constriction (ISO beat; ISO) was compared with the preceding basal
heartbeat (Basal). These beat-to-beat interventions allow selective
afterload elevation without neurohumoral activation, pericardial
constraint, and preload or long-term load history changes.54 After
each occlusion, the animal was allowed to stabilize for several
heartbeats. Hemodynamic recordings were made with ventilation
suspended at end-expiration. Parameters were converted on-line to
digital data with a sampling frequency of 1000 Hz. Pmax, dP/dtmax,
dP/dtmin, and EDP were measured. Relaxation rate was estimated
with the time constant t by fitting the ISO pressure fall to a mono-
exponential function. Diastolic intolerance to acute afterload was
assessed by computing the difference between EDP after and before
an ISO cycle, as previously reported.26
Myocardial multicellular muscle preparations
Fourteen days after PAN or vehicle injection, rats were anesthetized
and a left thoracotomy was performed. The beating heart was
quickly excised and immersed in modified Krebs–Ringer solution
containing (in mM) 93 NaCl, 5.0 KCl, 1.0 MgSO4, 1.2 KH2PO4, 10
Glucose, 1.25 CaCl2, 20 NaHCO3, 1.0 NaH2PO4, 20 Na2H3O2, 5 UI /l
regular insulin with cardioplegic 2,3-butanedione monoxime
(2.5%), equilibrated with a O2/CO2 mixture (95:5). Thin muscle
strips were carefully isolated from LV papillary muscles under a
dissecting microscope (Leica, Wilde M651), mounted horizontally
in a 5-ml organ bath and attached to an electromagnetic length-
tension transducer (University of Antwerp; Belgium). Twenty
minutes later, bathing solutions were replaced by modified
Krebs–Ringer solution without 2,3-butanedione monoxime. Preload
was estimated according to muscle dimensions, and electrical
stimulation was set 10% above threshold at a frequency of 0.5 Hz.
Muscles were stabilized and the experimental protocol began once
three comparable basal isotonic and isometric contractions were
separately recorded with an interval of at least 10 min. Temperature
was kept at 351C and pH 7.35–7.45 throughout the experimental
protocol. Isometric FFRs were obtained in PAN and Control by
stepping up the frequency of stimulation at 3-min intervals and
sequentially recording five contractions at 0.5 Hz, 1.0 Hz, 2.0 Hz,
and 3.0 Hz. The analyzed parameters included AT, dT/dtmax, dT/
dtmin, peak isotonic shortening, dL/dtmax, dL/dtmin, time to half
relaxation, and time to dL/dtmin (tdL/dtmin). AT was computed from
the weight and length of the muscle strip assuming an ellipsoidal
shape. Muscle maximum cross-sectional diameters measured on a
microscope (Leica) were similar in PAN (5537108mm) and Control
(484777 mm).
Statistical analysis
Results are mean7s.e. Repeated measures two-way analysis of
variance followed by Student–Newman–Keuls method for multiple
comparisons was applied to data from FFR in intact muscle strip
preparations. On all other instances, comparisons were performed
using Student’s unpaired t-test; two-tailed values of Po0.05 were
considered statistically significant.
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